𝓤𝓷𝓲𝓽𝓮𝓭 𝓝𝓮𝔀𝓼

Reports suggest AstraZeneca has engaged in discussions with its US counterpart, Bristol Myers Squibb, regarding a potential merger that could establish a pharmaceutical behemoth valued at over £300 billion.

The Financial Times indicated that these talks between the two drugmakers have been ongoing in recent months.

Such a consolidation would represent one of the largest transactions in the industry’s history, potentially forming the world’s fourth-largest pharmaceutical entity.

While sources suggest a deal could progress, they also cautioned that it “may be delayed or fall apart.”

AstraZeneca has declined to comment on the speculation. Bristol Myers Squibb (BMS) has been approached for comment.

Prior to these reports, Cambridge-based AstraZeneca stood as the UK’s second most valuable company, boasting a market capitalisation of approximately £196 billion.

Nevertheless, shares in the company fell by 6.1 per cent to 11,860p early on Monday.

New York-listed BMS focuses on cardiovascular and oncology treatments and is currently worth around £133 billion.

Any deal would be likely to face significant regulatory hurdles, amid significant scrutiny over the sector from competition and antitrust watchdogs.

A merger would be likely to be assessed by the Trump administration’s antitrust authorities, who have sought to increase domestic investment under President Donald Trump’s leadership.

A move comes amid efforts from AstraZeneca to grow its foothold in the US under boss Pascal Soriot.

The FTSE 100 firm completed a new additional listing on the New York Stock Exchange in June as a result, in a blow to the London markets.

Chris Beauchamp, chief market analyst at IG, said: “Companies saying one thing and doing another is a well-trodden path, and AstraZeneca joins in with the reports of a proposed alliance with Bristol Myers Squibb, having only said recently that it didn’t need M&A (mergers and acquisitions) to hit its targets.

“Though a rare example of a big UK firm buying a smaller US firm is something to warm the cockles of the British heart, it risks the departure of yet another national champion, and in any case the pair’s large cancer divisions is a major hurdle to a successful deal.”

Russ Mould, investment director at AJ Bell, said: “The speculated blockbuster merger between AstraZeneca and US rival Bristol Myers Squibb would have implications outside of the pharmaceutical sector.

“Assuming it went through, AstraZeneca would likely overtake HSBC to become comfortably the largest company on the FTSE 100.

“However, the fear will be that such a move, coming on top of the company’s recent direct listing in New York, would pull its centre of gravity across the Atlantic and ultimately see the UK stock market lose one of its crown jewels.

“Current CEO Pascal Soriot was a big player in the company’s decision to reject a takeover bid from Pfizer for £70 billion in 2014 and has been vindicated in the interim.

“A tie-up with Bristol Myers Squibb could help the business to reach its ambitious revenue goals, with North America already a key source of growth.

“The initial market reaction to the reports is highly circumspect, reflecting understandable caution about the scale of the deal. Major transactions of this kind often run into difficulties around integration and matching up different workplace cultures.

“Getting a deal across the line could be as difficult as putting together a 10,000-piece jigsaw with the companies’ overlapping focus in oncology likely to attract scrutiny from competition authorities.

“Political pressure might also be brought to bear, particularly on these shores given the importance of AstraZeneca to UK plc.”